Developer docs
API playgroundTry for free, no card

Search company profiles

BN ImmunoTherapeutics

Full company profile

uuid002mo3y

Namestring
BN ImmunoTherapeutics
Legal namestring
Bavarian Nordic A/S
Company typeenum
Public
Founded yearint
1994
Descriptiontext

BN ImmunoTherapeutics was a cancer immunotherapy company that was acquired by Bavarian Nordic in 2009 and has since been integrated into Bavarian Nordic's operations; standalone data for BN ImmunoTherapeutics is no longer available. The integrated entity, Bavarian Nordic, is a global vaccine company headquartered in Hellerup, Denmark, founded in 1994 and listed on Nasdaq Copenhagen since 1998. It specializes in the research, development, and manufacturing of vaccines built on viral vector technology, centered on its proprietary Modified Vaccinia Ankara (MVA-BN) platform, with 30+ years of vaccine development expertise. Its core products include JYNNEOS/IMVAMUNE/IMVANEX (smallpox/mpox, approved in 70+ countries), Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vaxchora (cholera), VIMKUNYA (chikungunya, with recent approvals across FDA, EC, MHRA, Swissmedic, and Health Canada), and Vivotif (typhoid).

The company operates a two-segment business model. In the public preparedness segment, it supplies governments and supranational organizations with smallpox/mpox vaccines under multi-year procurement contracts, notably including a large US BARDA contract for JYNNEOS. In the commercial travel vaccines segment, it markets Rabipur/RabAvert, Encepur, Vaxchora, VIMKUNYA, and Vivotif to travelers through pharmacies, travel clinics, and HCP portals (BN Assist in the US, BN Online in Canada and Europe). It employs more than 1,600 people across R&D, live-virus manufacturing in Denmark and Switzerland (Kvistgaard and Bern), and global commercialization.

Revenue mechanics blend long-dated government preparedness contracts, which provide predictable volume with lumpier order timing, with shorter-cycle commercial travel vaccine sales that depend on travel patterns and outbreak-driven demand. Recent strategic emphasis is on expanding the commercial vaccine footprint globally (notably through VIMKUNYA approvals and the Serum Institute of India partnership), extending JYNNEOS into pediatric populations via EMA, and scaling manufacturing capacity to support both public preparedness and commercial growth.

Short descriptiontext

BN ImmunoTherapeutics was acquired by Bavarian Nordic in 2009; the integrated company is a global vaccine developer and manufacturer based in Denmark, using its proprietary MVA-BN viral vector platform to supply smallpox/mpox vaccines to governments and travel vaccines (rabies, chikungunya, cholera, typhoid, tick-borne encephalitis) to travelers across 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immuno-therapeutics development, biopharmaceutical research, immunology therapeutics, vaccine development, infectious disease therapeutics
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immuno-therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Product Sales
TypeOne Time License
Description

Revenue generated from sale of commercial vaccines including travel vaccines (Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Vimkunya) and government preparedness vaccines (JYNNEOS/IMVAMUNE/IMVANEX for smallpox/mpox)

bavarian-nordic.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Technology or R&D, Personnel
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1JYNNEOS® / IMVAMUNE® / IMVANEX®
Description

Smallpox +/- Monkeypox (Mpox) Vaccine, Live, Non-replicating. Marketed under different names in different regions.

bavarian-nordic.com
+5 more records
Core offering1 text field

BN ImmunoTherapeutics was a biotechnology company focused on immuno-therapeutics, as suggested by its name. The company was acquired by Bavarian Nordic in 2009 and no longer operates as a standalone entity; the input does not specify the particular therapeutic candidates, modalities, or indications the company pursued.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Chikungunya vaccine VIMKUNYA approved by Health Canada (June 2026) - fifth global regulatory approval
+2 more records
Product overview1 text field

Bavarian Nordic is a global vaccine company with a focused portfolio of travel vaccines and public health preparedness vaccines. The company offers a portfolio of commercial vaccines including JYNNEOS®/IMVAMUNE®/IMVANEX® (smallpox/mpox vaccine), Rabipur®/RabAvert® (rabies vaccine), Encepur® (tick-borne encephalitis), Vaxchora® (cholera), VIMKUNYA™ (chikungunya), and Vivotif® (typhoid). The company also has a pipeline product (MVA-BN WEV) in Phase 2 for equine encephalitis. The company operates its own commercial-scale manufacturing facilities in Denmark and Switzerland.

Product and service1 record
1Immuno-therapeutic assets (pre-acquisition pipeline)
CategoryImmuno-therapeutics
Description

Pre-acquisition immuno-therapeutic assets of BN ImmunoTherapeutics; specific candidates, indications, modalities, or commercial products are not documented in the input data.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Bavarian Nordic and Serum Institute of India expanded their strategic partnership with a Chikungunya vaccine manufacturing agreement. This partnership expands global access to the chikungunya vaccine VIMKUNYA through Serum Institute's manufacturing capabilities.

2U.S. Government
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Development contracts with the US government for MVA-BN WEV vaccine candidate addressing western, eastern and Venezuelan equine encephalitis viruses. Bavarian Nordic is also a preferred supplier of smallpox/mpox vaccines to the US government.

bavarian-nordic.com
3Network of Partners Worldwide
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

A network of partners worldwide to expand capacity and supply as needed for vaccine manufacturing and distribution.

bavarian-nordic.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Moderna is a broader incumbent in the vaccine space with an mRNA platform and a growing infectious disease vaccine portfolio, including mpox vaccine candidates that compete with Bavarian Nordic's JYNNEOS franchise. As a much larger company with multiple approved products globally, Moderna competes across several of Bavarian Nordic's preparedness and travel vaccine markets.

TypeDirect peer
Description

Emergent BioSolutions is a direct peer in the biodefense and public preparedness vaccine space, historically focused on anthrax and smallpox countermeasures sold to U.S. government agencies. Like Bavarian Nordic, Emergent depends heavily on BARDA and similar federal preparedness contracts, and the two companies directly compete for smallpox/mpox preparedness procurement.

3Sanofi Pasteur
TypeBroad incumbent
Description

Sanofi Pasteur operates one of the world's largest vaccine franchises spanning pediatric, travel, and endemic disease segments. It competes with Bavarian Nordic's travel vaccines (especially rabies and TBE where it sells VERORAB and other established products) and is a broad incumbent in the same industry space.

4Valneva
TypeDirect peer
Description

Valneva is a direct competitor in travel and endemic infectious disease vaccines, particularly with IXCHIQ (live-attenuated chikungunya vaccine) competing directly against Bavarian Nordic's VIMKUNYA. Both companies are specialty vaccine players focused on travel health markets and have similar commercial infrastructure in Europe and North America.

TypeEmerging player
Description

Novavax is an emerging vaccine specialist focused on recombinant protein nanoparticle platforms, with COVID-19 and broader infectious disease pipeline ambitions. While its portfolio overlaps with Bavarian Nordic only loosely today, it is a comparable emerging vaccine player navigating scale-up, commercialization, and government contracting challenges.

TypeBroad incumbent
Description

GSK is a broad incumbent in vaccines, with a global portfolio that historically included the Rabipur/RabAvert and Encepur products Bavarian Nordic acquired in 2019. Although those specific brands moved to Bavarian Nordic, GSK remains a peer in travel health and broader vaccine markets and previously employed several of Bavarian Nordic's current commercial leaders.

TypeBroad incumbent
Description

Merck operates a global vaccine franchise (Gardasil, ProQuad, Vaxneuvance) and competes broadly in the infectious disease vaccine category. While Merck's portfolio skews pediatric and oncology-adjacent, it is a relevant broad incumbent peer for benchmarking vaccine commercialization capabilities and government contracting scale.

TypeBroad incumbent
Description

Pfizer is a broad incumbent in vaccines (Prevnar franchise, COVID-19 partnership, mRNA pipeline including mpox candidates) and competes with Bavarian Nordic in U.S. preparedness procurement and in travel vaccines for endemic infectious diseases.

TypeBroad incumbent
Description

Takeda operates a global vaccine franchise acquired from Baxter (including travel vaccines such as Japanese encephalitis) and holds pandemic preparedness contracts with multiple governments. As a Japanese broad incumbent with vaccine manufacturing, Takeda is comparable to Bavarian Nordic's global preparedness positioning.

TypeBroad incumbent
Description

Seqirus, the vaccines arm of CSL Limited, is a broad incumbent in specialty vaccines, particularly influenza but also travel and endemic disease vaccines. Its scale, biosecurity-grade manufacturing footprint, and pandemic preparedness positioning parallel aspects of Bavarian Nordic's business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries12 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BN ImmunoTherapeutics

Immuno-therapeuticsbavarian-nordic.com

BN ImmunoTherapeutics was acquired by Bavarian Nordic in 2009; the integrated company is a global vaccine developer and manufacturer based in Denmark, using its proprietary MVA-BN viral vector platform to supply smallpox/mpox vaccines to governments and travel vaccines (rabies, chikungunya, cholera, typhoid, tick-borne encephalitis) to travelers across 70+ countries.

What BN ImmunoTherapeutics does

BN ImmunoTherapeutics was a cancer immunotherapy company that was acquired by Bavarian Nordic in 2009 and has since been integrated into Bavarian Nordic's operations; standalone data for BN ImmunoTherapeutics is no longer available. The integrated entity, Bavarian Nordic, is a global vaccine company headquartered in Hellerup, Denmark, founded in 1994 and listed on Nasdaq Copenhagen since 1998. It specializes in the research, development, and manufacturing of vaccines built on viral vector technology, centered on its proprietary Modified Vaccinia Ankara (MVA-BN) platform, with 30+ years of vaccine development expertise. Its core products include JYNNEOS/IMVAMUNE/IMVANEX (smallpox/mpox, approved in 70+ countries), Rabipur/RabAvert (rabies), Encepur (tick-borne encephalitis), Vaxchora (cholera), VIMKUNYA (chikungunya, with recent approvals across FDA, EC, MHRA, Swissmedic, and Health Canada), and Vivotif (typhoid).

The company operates a two-segment business model. In the public preparedness segment, it supplies governments and supranational organizations with smallpox/mpox vaccines under multi-year procurement contracts, notably including a large US BARDA contract for JYNNEOS. In the commercial travel vaccines segment, it markets Rabipur/RabAvert, Encepur, Vaxchora, VIMKUNYA, and Vivotif to travelers through pharmacies, travel clinics, and HCP portals (BN Assist in the US, BN Online in Canada and Europe). It employs more than 1,600 people across R&D, live-virus manufacturing in Denmark and Switzerland (Kvistgaard and Bern), and global commercialization.

Revenue mechanics blend long-dated government preparedness contracts, which provide predictable volume with lumpier order timing, with shorter-cycle commercial travel vaccine sales that depend on travel patterns and outbreak-driven demand. Recent strategic emphasis is on expanding the commercial vaccine footprint globally (notably through VIMKUNYA approvals and the Serum Institute of India partnership), extending JYNNEOS into pediatric populations via EMA, and scaling manufacturing capacity to support both public preparedness and commercial growth.

BN ImmunoTherapeutics firmographics

Firmographics
Name
BN ImmunoTherapeutics
Legal name
Bavarian Nordic A/S
Website
https://bavarian-nordic.com
Company type
Public
Founded year
1994
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
BN ImmunoTherapeutics was acquired by Bavarian Nordic in 2009; the integrated company is a global vaccine developer and manufacturer based in Denmark, using its proprietary MVA-BN viral vector platform to supply smallpox/mpox vaccines to governments and travel vaccines (rabies, chikungunya, cholera, typhoid, tick-borne encephalitis) to travelers across 70+ countries.
Ownership category
akta.pro rank

BN ImmunoTherapeutics industry classification

Industry
Product category
Immuno-therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAEAN
Vaccine Procurement, Tendering & Immunization Supply Programs

Keywords

  • Immuno-therapeutics development
  • Biopharmaceutical research
  • Immunology therapeutics
  • Vaccine development
  • Infectious disease therapeutics

Where BN ImmunoTherapeutics is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices13 records

Markets served

BN ImmunoTherapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel

Revenue model

  1. Vaccine Product Sales: Revenue generated from sale of commercial vaccines including travel vaccines (Rabipur/RabAvert, Encepur, Vivotif, Vaxchora, Vimkunya) and government preparedness vaccines (JYNNEOS/IMVAMUNE/IMVANEX for smallpox/mpox)

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

BN ImmunoTherapeutics product offering

Product offering

Core offering

BN ImmunoTherapeutics was a biotechnology company focused on immuno-therapeutics, as suggested by its name. The company was acquired by Bavarian Nordic in 2009 and no longer operates as a standalone entity; the input does not specify the particular therapeutic candidates, modalities, or indications the company pursued.

Product overview

Bavarian Nordic is a global vaccine company with a focused portfolio of travel vaccines and public health preparedness vaccines. The company offers a portfolio of commercial vaccines including JYNNEOS®/IMVAMUNE®/IMVANEX® (smallpox/mpox vaccine), Rabipur®/RabAvert® (rabies vaccine), Encepur® (tick-borne encephalitis), Vaxchora® (cholera), VIMKUNYA™ (chikungunya), and Vivotif® (typhoid). The company also has a pipeline product (MVA-BN WEV) in Phase 2 for equine encephalitis. The company operates its own commercial-scale manufacturing facilities in Denmark and Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

  • JYNNEOS® / IMVAMUNE® / IMVANEX®: Smallpox +/- Monkeypox (Mpox) Vaccine, Live, Non-replicating. Marketed under different names in different regions.
  • Rabipur® / RabAvert®
  • Encepur®
  • Vaxchora®
  • VIMKUNYA™
  • Vivotif®

Products and services

  • Immuno-therapeutic assets (pre-acquisition pipeline) Pre-acquisition immuno-therapeutic assets of BN ImmunoTherapeutics; specific candidates, indications, modalities, or commercial products are not documented in the input data.

Quantifiable outcome

  • Chikungunya vaccine VIMKUNYA approved by Health Canada (June 2026) - fifth global regulatory approval
  • +2 more outcomes

Companies that use BN ImmunoTherapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

BN ImmunoTherapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BN ImmunoTherapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Serum Institute of IndiacoreStrategic or Co-development Partner · 11 March 2026Bavarian Nordic and Serum Institute of India expanded their strategic partnership with a Chikungunya vaccine manufacturing agreement. This partnership expands global access to the chikungunya vaccine VIMKUNYA through Serum Institute's manufacturing capabilities.
  • U.S. GovernmentcoreStrategic or Co-development PartnerDevelopment contracts with the US government for MVA-BN WEV vaccine candidate addressing western, eastern and Venezuelan equine encephalitis viruses. Bavarian Nordic is also a preferred supplier of smallpox/mpox vaccines to the US government.
  • Network of Partners WorldwideminorChannel Partner/ Reseller/ DistributorA network of partners worldwide to expand capacity and supply as needed for vaccine manufacturing and distribution.

Scale indicators7 records

Recent moves8 records

Expansion highlights4 records

BN ImmunoTherapeutics competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Moderna is a broader incumbent in the vaccine space with an mRNA platform and a growing infectious disease vaccine portfolio, including mpox vaccine candidates that compete with Bavarian Nordic's JYNNEOS franchise. As a much larger company with multiple approved products globally, Moderna competes across several of Bavarian Nordic's preparedness and travel vaccine markets.
  • Sanofi Pasteur: Sanofi Pasteur operates one of the world's largest vaccine franchises spanning pediatric, travel, and endemic disease segments. It competes with Bavarian Nordic's travel vaccines (especially rabies and TBE where it sells VERORAB and other established products) and is a broad incumbent in the same industry space.
  • GSK: GSK is a broad incumbent in vaccines, with a global portfolio that historically included the Rabipur/RabAvert and Encepur products Bavarian Nordic acquired in 2019. Although those specific brands moved to Bavarian Nordic, GSK remains a peer in travel health and broader vaccine markets and previously employed several of Bavarian Nordic's current commercial leaders.
  • Merck & Co. Merck operates a global vaccine franchise (Gardasil, ProQuad, Vaxneuvance) and competes broadly in the infectious disease vaccine category. While Merck's portfolio skews pediatric and oncology-adjacent, it is a relevant broad incumbent peer for benchmarking vaccine commercialization capabilities and government contracting scale.
  • Pfizer: Pfizer is a broad incumbent in vaccines (Prevnar franchise, COVID-19 partnership, mRNA pipeline including mpox candidates) and competes with Bavarian Nordic in U.S. preparedness procurement and in travel vaccines for endemic infectious diseases.
  • Takeda Pharmaceutical (Vaccines): Takeda operates a global vaccine franchise acquired from Baxter (including travel vaccines such as Japanese encephalitis) and holds pandemic preparedness contracts with multiple governments. As a Japanese broad incumbent with vaccine manufacturing, Takeda is comparable to Bavarian Nordic's global preparedness positioning.
  • Seqirus (CSL): Seqirus, the vaccines arm of CSL Limited, is a broad incumbent in specialty vaccines, particularly influenza but also travel and endemic disease vaccines. Its scale, biosecurity-grade manufacturing footprint, and pandemic preparedness positioning parallel aspects of Bavarian Nordic's business model.

Direct peers

  • Emergent BioSolutions: Emergent BioSolutions is a direct peer in the biodefense and public preparedness vaccine space, historically focused on anthrax and smallpox countermeasures sold to U.S. government agencies. Like Bavarian Nordic, Emergent depends heavily on BARDA and similar federal preparedness contracts, and the two companies directly compete for smallpox/mpox preparedness procurement.
  • Valneva: Valneva is a direct competitor in travel and endemic infectious disease vaccines, particularly with IXCHIQ (live-attenuated chikungunya vaccine) competing directly against Bavarian Nordic's VIMKUNYA. Both companies are specialty vaccine players focused on travel health markets and have similar commercial infrastructure in Europe and North America.

Emerging players

  • Novavax: Novavax is an emerging vaccine specialist focused on recombinant protein nanoparticle platforms, with COVID-19 and broader infectious disease pipeline ambitions. While its portfolio overlaps with Bavarian Nordic only loosely today, it is a comparable emerging vaccine player navigating scale-up, commercialization, and government contracting challenges.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

BN ImmunoTherapeutics social profiles

Digital presence

BN ImmunoTherapeutics compliance and trust

Trust signal

Compliance6 records

BN ImmunoTherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BN ImmunoTherapeutics leadership team

Management profile

Number of profiles

BN ImmunoTherapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries12 records

BN ImmunoTherapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BN ImmunoTherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BN ImmunoTherapeutics

What does BN ImmunoTherapeutics do?

BN ImmunoTherapeutics was a biotechnology company focused on immuno-therapeutics, as suggested by its name. The company was acquired by Bavarian Nordic in 2009 and no longer operates as a standalone entity; the input does not specify the particular therapeutic candidates, modalities, or indications the company pursued.

Is BN ImmunoTherapeutics a public or private company?

BN ImmunoTherapeutics is a public company. It is classified as corporate owned and is currently operating.

When was BN ImmunoTherapeutics founded?

BN ImmunoTherapeutics was founded in 1994. It employs 1,001 to 5,000 people.

Where is BN ImmunoTherapeutics based?

BN ImmunoTherapeutics is headquartered in Copenhagen, Denmark, in the Europe region.

How does BN ImmunoTherapeutics make money?

One revenue line is on record: vaccine Product Sales.

Who are BN ImmunoTherapeutics's main competitors?

Broad incumbents on record are Moderna, Sanofi Pasteur, GSK, Merck & Co., Pfizer, Takeda Pharmaceutical (Vaccines) and Seqirus (CSL). Direct peers are Emergent BioSolutions and Valneva. Novavax is listed as an emerging player.

Does BN ImmunoTherapeutics have an API?

No public API is recorded for BN ImmunoTherapeutics.

What industry is BN ImmunoTherapeutics in?

BN ImmunoTherapeutics's product category is Immuno-therapeutics. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals